BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30389746)

  • 1. VEGFC Reduces Glomerular Albumin Permeability and Protects Against Alterations in VEGF Receptor Expression in Diabetic Nephropathy.
    Onions KL; Gamez M; Buckner NR; Baker SL; Betteridge KB; Desideri S; Dallyn BP; Ramnath RD; Neal CR; Farmer LK; Mathieson PW; Gnudi L; Alitalo K; Bates DO; Salmon AHJ; Welsh GI; Satchell SC; Foster RR
    Diabetes; 2019 Jan; 68(1):172-187. PubMed ID: 30389746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy.
    Oltean S; Qiu Y; Ferguson JK; Stevens M; Neal C; Russell A; Kaura A; Arkill KP; Harris K; Symonds C; Lacey K; Wijeyaratne L; Gammons M; Wylie E; Hulse RP; Alsop C; Cope G; Damodaran G; Betteridge KB; Ramnath R; Satchell SC; Foster RR; Ballmer-Hofer K; Donaldson LF; Barratt J; Baelde HJ; Harper SJ; Bates DO; Salmon AH
    J Am Soc Nephrol; 2015 Aug; 26(8):1889-904. PubMed ID: 25542969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial glycocalyx restoration by growth factors in diabetic nephropathy.
    Desideri S; Onions KL; Baker SL; Gamez M; El Hegni E Hussien H; Russell A; Satchell SC; Foster RR
    Biorheology; 2019; 56(2-3):163-179. PubMed ID: 31156139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adiponectin Reduces Glomerular Endothelial Glycocalyx Disruption and Restores Glomerular Barrier Function in a Mouse Model of Type 2 Diabetes.
    Fawaz S; Martin Alonso A; Qiu Y; Ramnath R; Stowell-Connolly H; Gamez M; May C; Down C; Coward RJ; Butler MJ; Welsh GI; Satchell SC; Foster RR
    Diabetes; 2024 Jun; 73(6):964-976. PubMed ID: 38530908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx.
    Crompton M; Ferguson JK; Ramnath RD; Onions KL; Ogier AS; Gamez M; Down CJ; Skinner L; Wong KH; Dixon LK; Sutak J; Harper SJ; Pontrelli P; Gesualdo L; Heerspink HL; Toto RD; Welsh GI; Foster RR; Satchell SC; Butler MJ
    JCI Insight; 2023 Mar; 8(5):. PubMed ID: 36749631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Podocyte vascular endothelial growth factor (Vegf₁₆₄) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes.
    Veron D; Bertuccio CA; Marlier A; Reidy K; Garcia AM; Jimenez J; Velazquez H; Kashgarian M; Moeckel GW; Tufro A
    Diabetologia; 2011 May; 54(5):1227-41. PubMed ID: 21318407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency.
    Wolf G; Schanze A; Stahl RA; Shankland SJ; Amann K
    Kidney Int; 2005 Oct; 68(4):1583-9. PubMed ID: 16164635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vegfa protects the glomerular microvasculature in diabetes.
    Sivaskandarajah GA; Jeansson M; Maezawa Y; Eremina V; Baelde HJ; Quaggin SE
    Diabetes; 2012 Nov; 61(11):2958-66. PubMed ID: 23093658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The VEGF-A inhibitor sFLT-1 improves renal function by reducing endothelial activation and inflammation in a mouse model of type 1 diabetes.
    Bus P; Scharpfenecker M; Van Der Wilk P; Wolterbeek R; Bruijn JA; Baelde HJ
    Diabetologia; 2017 Sep; 60(9):1813-1821. PubMed ID: 28620823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion of pro-angiogenic factor vasohibin-2 ameliorates glomerular alterations in a mouse diabetic nephropathy model.
    Masuda K; Tanabe K; Ujike H; Hinamoto N; Miyake H; Tanimura S; Sugiyama H; Sato Y; Maeshima Y; Wada J
    PLoS One; 2018; 13(4):e0195779. PubMed ID: 29641565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Klotho attenuates renal hypertrophy and glomerular injury in Ins2Akita diabetic mice.
    Kadoya H; Satoh M; Haruna Y; Sasaki T; Kashihara N
    Clin Exp Nephrol; 2016 Oct; 20(5):671-678. PubMed ID: 26586006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor-C, a potential paracrine regulator of glomerular permeability, increases glomerular endothelial cell monolayer integrity and intracellular calcium.
    Foster RR; Slater SC; Seckley J; Kerjaschki D; Bates DO; Mathieson PW; Satchell SC
    Am J Pathol; 2008 Oct; 173(4):938-48. PubMed ID: 18772335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Podocyte-specific chemokine (C-C motif) receptor 2 overexpression mediates diabetic renal injury in mice.
    You H; Gao T; Raup-Konsavage WM; Cooper TK; Bronson SK; Reeves WB; Awad AS
    Kidney Int; 2017 Mar; 91(3):671-682. PubMed ID: 27914709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitave and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetes.
    Bortoloso E; Del Prete D; Dalla Vestra M; Gambaro G; Saller A; Antonucci F; Baggio B; Anglani F; Fioretto P
    Eur J Endocrinol; 2004 Jun; 150(6):799-807. PubMed ID: 15191350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man.
    Hohenstein B; Hausknecht B; Boehmer K; Riess R; Brekken RA; Hugo CP
    Kidney Int; 2006 May; 69(9):1654-61. PubMed ID: 16541023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy.
    Jha JC; Thallas-Bonke V; Banal C; Gray SP; Chow BS; Ramm G; Quaggin SE; Cooper ME; Schmidt HH; Jandeleit-Dahm KA
    Diabetologia; 2016 Feb; 59(2):379-89. PubMed ID: 26508318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted glomerular angiopoietin-1 therapy for early diabetic kidney disease.
    Dessapt-Baradez C; Woolf AS; White KE; Pan J; Huang JL; Hayward AA; Price KL; Kolatsi-Joannou M; Locatelli M; Diennet M; Webster Z; Smillie SJ; Nair V; Kretzler M; Cohen CD; Long DA; Gnudi L
    J Am Soc Nephrol; 2014 Jan; 25(1):33-42. PubMed ID: 24009238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Monocyte Chemotactic Protein-1 Inhibition Modifies Renal Macrophages and Restores Glomerular Endothelial Glycocalyx and Barrier Function in Diabetic Nephropathy.
    Boels MGS; Koudijs A; Avramut MC; Sol WMPJ; Wang G; van Oeveren-Rietdijk AM; van Zonneveld AJ; de Boer HC; van der Vlag J; van Kooten C; Eulberg D; van den Berg BM; IJpelaar DHT; Rabelink TJ
    Am J Pathol; 2017 Nov; 187(11):2430-2440. PubMed ID: 28837800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycosaminoglycan regulation by VEGFA and VEGFC of the glomerular microvascular endothelial cell glycocalyx in vitro.
    Foster RR; Armstrong L; Baker S; Wong DW; Wylie EC; Ramnath R; Jenkins R; Singh A; Steadman R; Welsh GI; Mathieson PW; Satchell SC
    Am J Pathol; 2013 Aug; 183(2):604-16. PubMed ID: 23770346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schisandra chinensis fruit extract attenuates albuminuria and protects podocyte integrity in a mouse model of streptozotocin-induced diabetic nephropathy.
    Zhang M; Liu M; Xiong M; Gong J; Tan X
    J Ethnopharmacol; 2012 May; 141(1):111-8. PubMed ID: 22353431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.